FORM PTO-1449 (Modified)		Atty.	Atty. Docket No. PH1015DB			Serial No. Notyctknown			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Applicants: Dolle et al.						
(37 CFR 1.98	(b))	Filin	g Date: I	December 8, 19	997	Group:	1613		
		U.S. PA	TENT	DOCUME	NTS				
Evaminar	Dotont	Iceno					Eiling Data		

Examiner Initial		Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
DI	AA	5,120,718	6/9/92	Goldman et al.	514	32	
						-	
						<u> </u>	
						 	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Document		Country or Patent Office			Trans	slation
	Number	Date	Patent Office	Class	Subclass	YES	NO
						-	

OTHER DOCUMENTS

(including Author, Title, Date, Relevant Pages, Place of Publication)

		(including Author, Title, Date, Relevant Pages, Place of Publication)				
Dk	CA	Rich et al., "Design and Discovery of Aspartyl Protease Inhibitors Mechanistic and Clinical Implications," In Conformationally Directed Drug Design, Julius A. Vida and Maxwell Gordon, eds. ACS Symposium Series, American Chemical Society, Washington, D.C., Chapter 10, pp. 211-237, 1984.				
	<u> </u>					
Examine	:	DOMINIC KEATING Date Considered: 6/17/98				

EXAMINER: Initial citation considered. Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant.